Sun Pharma says aiming for mid-to-high single digit consolidated topline growth in FY26

Sun Pharma says aiming for mid-to-high single digit consolidated topline growth in FY26

Sun Pharmaceutical Industries on December 26 said that it targets a mid to high single digit consolidated topline growth for FY26. The pharma giant added that its focus remains on sustainable and profitable growth, along with improving overall return ratios.

The shares of Sun Pharma fell nearly 1 percent to close at Rs 1,720 apiece, extending losses for the third consecutive session. This is the lowest closing level seen by the stock in more than a month.

In an investor presentation released today, Sun Pharma said that its gross sales stood at Rs 52,041 crore in the financial year 2025, with India accounting for 33 percent of the formulations. EBITDA stood at Rs 15,272 crore with an EBITDA margin of 29 percent.

It added that it held its market position as the largest pharma company in India with a 8.3 percent markt share, and was ranked number 1 by prescriptions with 13 classes of prescribers.

Sun Pharma’s focus areas involve investing in research and development (R&D) to further build its pipeline of innovative medicines. The company added that it will focus on developing complex products across multiple dosage forms.

In the US market, Sun Pharma will continue to focus on complex generics and high entry barrier segments, it said. In India, the company will focus on continuously innovating to ensure high brand equity with doctors and evaluating in-licensing opportunities for latest generation patented products. In the emerging markets segment, the company will aim to enhance its innovative product basket, as per the presentation.

Sun Pharma share price:

Sun Pharma shares have fallen nearly 2 percent in the past five days, and around 5 percent in the past one month. The stock has however risen over 3 percent in the past six months.

Its P/E ratio currently stands at over 40.